pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
LILLY · news · pharmadog
← back to LILLY
News mentioning LILLY
309
stories
10d
STAT+: Pharmalittle: We’re reading about Trump’s plan for tariffs on generics, a Merck and Gilead HIV pill, and more
stat
10d
US ‘eroding’ lead in rare diseases a matter of national security: Report
biospace
10d
Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2
biospace
10d
AI data becomes sticking point in biopharma dealmaking
biospace
10d
Novo sues Lilly over 'deceptive' ads comparing GLP-1 drug doses
endpoints
10d
Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesity
biospace
11d
Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs
biopharma dive
11d
Dimension restocks with $800M to capitalize on AI’s ‘rapid ascent’
biopharma dive
11d
STAT+: Anthropic deepens work with rare disease drugs
stat
11d
STAT+: Pharmalittle: We’re reading about Novo suing Lilly over ‘deceptive’ ads, a fugitive’s secret life in biotech, and more
stat
11d
Novartis stays 'geography-agnostic' in dealmaking amid flurry of China deals
biospace
11d
‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx deal
fiercebiotech
11d
STAT+: Nabla’s new CEO on plan to gain market share in a competitive AI scribe environment
stat
11d
STAT+: Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’
stat
11d
Jupiter enters psychedelics space with $100M deal for PharmAla's MDMA drug
fiercebiotech
11d
Recon: Novo sues Lilly over weight-loss drug ads; Gilead, Merck say HIV pill keeps HIV suppressed in two Phase 3 trials
raps
12d
Pain drugmaker Latigo outlines plans to go public
biopharma dive
12d
Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics
biospace
12d
J&J, AbbVie said to have also looked at AtaiBeckley before Lilly’s $2.8B deal
endpoints
12d
STAT+: A most-wanted fugitive appears to have been secretly working as a biotech executive
stat
12d
Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker
biopharma dive
12d
STAT+: Bristol Myers Squibb becomes latest company to claim it’s building pharma’s largest NVIDIA AI supercomputer
stat
12d
Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds
fiercebiotech
12d
BMS expands AI footprint with Nvidia, aiming for ‘most powerful AI factory in life sciences’
fiercebiotech
12d
STAT+: Telemedicine company touted by Novo Nordisk stressed profits over patient safety, ex-workers say
stat
12d
Type 1 diabetes pipeline making ‘remarkable progress’ toward insulin independence
biospace
14d
‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics
fiercebiotech
15d
STAT+: The end for GSK’s chronic cough treatment
stat
15d
Compounders maintain a firm grip on the GLP-1 market
biopharma dive
15d
STAT+: Pharmalittle: We’re reading about rising drug shortages, GSK coughing up a trial loss, and more
stat
← prev
page 3 of 11
next →
